Insulin micro-secretion in Type 1 diabetes and related microRNA profiles

Abstract The aim of this cross-sectional study was to compare plasma C-peptide presence and levels in people without diabetes (CON) and with Type 1 diabetes and relate C-peptide status to clinical factors. In a subset we evaluated 50 microRNAs (miRs) previously implicated in beta-cell death and asso...

Full description

Bibliographic Details
Main Authors: Andrzej S. Januszewski, Yoon Hi Cho, Mugdha V. Joglekar, Ryan J. Farr, Emma S. Scott, Wilson K. M. Wong, Luke M. Carroll, Yik W. Loh, Paul Z. Benitez-Aguirre, Anthony C. Keech, David N. O’Neal, Maria E. Craig, Anandwardhan A. Hardikar, Kim C. Donaghue, Alicia J. Jenkins
Format: Article
Language:English
Published: Nature Publishing Group 2021-06-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-90856-6
id doaj-b1ec56fdb12a4c0cb5cb32be78d2f006
record_format Article
spelling doaj-b1ec56fdb12a4c0cb5cb32be78d2f0062021-06-06T11:37:42ZengNature Publishing GroupScientific Reports2045-23222021-06-0111111110.1038/s41598-021-90856-6Insulin micro-secretion in Type 1 diabetes and related microRNA profilesAndrzej S. Januszewski0Yoon Hi Cho1Mugdha V. Joglekar2Ryan J. Farr3Emma S. Scott4Wilson K. M. Wong5Luke M. Carroll6Yik W. Loh7Paul Z. Benitez-Aguirre8Anthony C. Keech9David N. O’Neal10Maria E. Craig11Anandwardhan A. Hardikar12Kim C. Donaghue13Alicia J. Jenkins14NHMRC Clinical Trials Centre, University of SydneyDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyNHMRC Clinical Trials Centre, University of SydneyDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyDepartment of Medicine, University of MelbourneDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyDiscipline of Paediatrics and Child Health, University of SydneyNHMRC Clinical Trials Centre, University of SydneyAbstract The aim of this cross-sectional study was to compare plasma C-peptide presence and levels in people without diabetes (CON) and with Type 1 diabetes and relate C-peptide status to clinical factors. In a subset we evaluated 50 microRNAs (miRs) previously implicated in beta-cell death and associations with clinical status and C-peptide levels. Diabetes age of onset was stratified as adult (≥ 18 y.o) or childhood (< 18 y.o.), and diabetes duration was stratified as ≤ 10 years, 10–20 years and > 20 years. Plasma C-peptide was measured by ultrasensitive ELISA. Plasma miRs were quantified using TaqMan probe-primer mix on an OpenArray platform. C-peptide was detectable in 55.3% of (n = 349) people with diabetes, including 64.1% of adults and 34.0% of youth with diabetes, p < 0.0001 and in all (n = 253) participants without diabetes (CON). C-peptide levels, when detectable, were lower in the individuals with diabetes than in the CON group [median lower quartile (LQ)–upper quartile (UQ)] 5.0 (2.6–28.7) versus 650.9 (401.2–732.4) pmol/L respectively, p < 0.0001 and lower in childhood versus adult-onset diabetes [median (LQ–UQ) 4.2 (2.6–12.2) pmol/L vs. 8.0 (2.3–80.5) pmol/L, p = 0.02, respectively]. In the childhood-onset group more people with longer diabetes duration (> 20 years) had detectable C-peptide (60%) than in those with shorter diabetes duration (39%, p for trend < 0.05). Nine miRs significantly correlated with detectable C-peptide levels in people with diabetes and 16 miRs correlated with C-peptide levels in CON. Our cross-sectional study results are supportive of (a) greater beta-cell function loss in younger onset Type 1 diabetes; (b) persistent insulin secretion in adult-onset diabetes and possibly regenerative secretion in childhood-onset long diabetes duration; and (c) relationships of C-peptide levels with circulating miRs. Confirmatory clinical studies and related basic science studies are merited.https://doi.org/10.1038/s41598-021-90856-6
collection DOAJ
language English
format Article
sources DOAJ
author Andrzej S. Januszewski
Yoon Hi Cho
Mugdha V. Joglekar
Ryan J. Farr
Emma S. Scott
Wilson K. M. Wong
Luke M. Carroll
Yik W. Loh
Paul Z. Benitez-Aguirre
Anthony C. Keech
David N. O’Neal
Maria E. Craig
Anandwardhan A. Hardikar
Kim C. Donaghue
Alicia J. Jenkins
spellingShingle Andrzej S. Januszewski
Yoon Hi Cho
Mugdha V. Joglekar
Ryan J. Farr
Emma S. Scott
Wilson K. M. Wong
Luke M. Carroll
Yik W. Loh
Paul Z. Benitez-Aguirre
Anthony C. Keech
David N. O’Neal
Maria E. Craig
Anandwardhan A. Hardikar
Kim C. Donaghue
Alicia J. Jenkins
Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
Scientific Reports
author_facet Andrzej S. Januszewski
Yoon Hi Cho
Mugdha V. Joglekar
Ryan J. Farr
Emma S. Scott
Wilson K. M. Wong
Luke M. Carroll
Yik W. Loh
Paul Z. Benitez-Aguirre
Anthony C. Keech
David N. O’Neal
Maria E. Craig
Anandwardhan A. Hardikar
Kim C. Donaghue
Alicia J. Jenkins
author_sort Andrzej S. Januszewski
title Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
title_short Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
title_full Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
title_fullStr Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
title_full_unstemmed Insulin micro-secretion in Type 1 diabetes and related microRNA profiles
title_sort insulin micro-secretion in type 1 diabetes and related microrna profiles
publisher Nature Publishing Group
series Scientific Reports
issn 2045-2322
publishDate 2021-06-01
description Abstract The aim of this cross-sectional study was to compare plasma C-peptide presence and levels in people without diabetes (CON) and with Type 1 diabetes and relate C-peptide status to clinical factors. In a subset we evaluated 50 microRNAs (miRs) previously implicated in beta-cell death and associations with clinical status and C-peptide levels. Diabetes age of onset was stratified as adult (≥ 18 y.o) or childhood (< 18 y.o.), and diabetes duration was stratified as ≤ 10 years, 10–20 years and > 20 years. Plasma C-peptide was measured by ultrasensitive ELISA. Plasma miRs were quantified using TaqMan probe-primer mix on an OpenArray platform. C-peptide was detectable in 55.3% of (n = 349) people with diabetes, including 64.1% of adults and 34.0% of youth with diabetes, p < 0.0001 and in all (n = 253) participants without diabetes (CON). C-peptide levels, when detectable, were lower in the individuals with diabetes than in the CON group [median lower quartile (LQ)–upper quartile (UQ)] 5.0 (2.6–28.7) versus 650.9 (401.2–732.4) pmol/L respectively, p < 0.0001 and lower in childhood versus adult-onset diabetes [median (LQ–UQ) 4.2 (2.6–12.2) pmol/L vs. 8.0 (2.3–80.5) pmol/L, p = 0.02, respectively]. In the childhood-onset group more people with longer diabetes duration (> 20 years) had detectable C-peptide (60%) than in those with shorter diabetes duration (39%, p for trend < 0.05). Nine miRs significantly correlated with detectable C-peptide levels in people with diabetes and 16 miRs correlated with C-peptide levels in CON. Our cross-sectional study results are supportive of (a) greater beta-cell function loss in younger onset Type 1 diabetes; (b) persistent insulin secretion in adult-onset diabetes and possibly regenerative secretion in childhood-onset long diabetes duration; and (c) relationships of C-peptide levels with circulating miRs. Confirmatory clinical studies and related basic science studies are merited.
url https://doi.org/10.1038/s41598-021-90856-6
work_keys_str_mv AT andrzejsjanuszewski insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT yoonhicho insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT mugdhavjoglekar insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT ryanjfarr insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT emmasscott insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT wilsonkmwong insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT lukemcarroll insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT yikwloh insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT paulzbenitezaguirre insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT anthonyckeech insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT davidnoneal insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT mariaecraig insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT anandwardhanahardikar insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT kimcdonaghue insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
AT aliciajjenkins insulinmicrosecretionintype1diabetesandrelatedmicrornaprofiles
_version_ 1721393871686991872